Ptc Therapeutics Financials
This page shows Ptc Therapeutics (PTCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ptc Therapeutics has an operating margin of -37.5%, meaning the company retains $-38 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -46.9% the prior year.
Ptc Therapeutics's revenue declined 14% year-over-year, from $937.8M to $806.8M. This contraction results in a growth score of 0/100.
With a current ratio of 2.35, Ptc Therapeutics holds $2.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.
While Ptc Therapeutics generated -$107.7M in operating cash flow, capex of $6.5M consumed most of it, leaving -$114.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Ptc Therapeutics passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Ptc Therapeutics generates $0.30 in operating cash flow (-$107.7M OCF vs -$363.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Ptc Therapeutics generated $806.8M in revenue in fiscal year 2024. This represents a decrease of 14.0% from the prior year.
Ptc Therapeutics's EBITDA was -$226.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 11.8% from the prior year.
Ptc Therapeutics generated -$114.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 38.9% from the prior year.
Ptc Therapeutics reported -$363.3M in net income in fiscal year 2024. This represents an increase of 42.0% from the prior year.
Ptc Therapeutics earned $-4.73 per diluted share (EPS) in fiscal year 2024. This represents an increase of 43.5% from the prior year.
Ptc Therapeutics held $779.7M in cash against $285.4M in long-term debt as of fiscal year 2024.
Ptc Therapeutics had 78M shares outstanding in fiscal year 2024. This represents an increase of 2.6% from the prior year.
Ptc Therapeutics's operating margin was -37.5% in fiscal year 2024, reflecting core business profitability. This is up 9.4 percentage points from the prior year.
Ptc Therapeutics's net profit margin was -45.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 21.8 percentage points from the prior year.
Ptc Therapeutics invested $534.5M in research and development in fiscal year 2024. This represents a decrease of 19.8% from the prior year.
Ptc Therapeutics invested $6.5M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 77.1% from the prior year.
PTCT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $211.0M+18.0% | $178.9M-84.8% | $1.2B+451.7% | $213.2M+14.2% | $186.7M-11.1% | $210.1M-31.6% | $307.1M+56.2% | $196.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $100.2M-11.4% | $113.0M+3.7% | $109.0M-12.7% | $124.8M-5.6% | $132.2M+13.8% | $116.1M-4.3% | $121.4M-26.1% | $164.2M |
| SG&A Expenses | $84.0M-1.4% | $85.3M+5.3% | $81.0M-4.4% | $84.7M+21.8% | $69.5M-5.1% | $73.3M-4.0% | $76.3M-5.7% | $80.9M |
| Operating Income | $3.0M+108.6% | -$35.0M-103.6% | $970.2M+697.5% | -$162.4M-303.8% | -$40.2M+11.5% | -$45.5M-881.0% | $5.8M+104.9% | -$118.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$39.0M-528.2% | -$6.2M-109.8% | $63.3M+319.6% | -$28.8M-314.3% | $13.4M+95.4% | $6.9M+646.5% | -$1.3M+96.3% | -$33.6M |
| Net Income | $15.9M+124.5% | -$64.8M-107.5% | $866.6M+1415.2% | -$65.9M+33.6% | -$99.2M-8.3% | -$91.6M+41.2% | -$155.8M-17.2% | -$133.0M |
| EPS (Diluted) | $0.20+124.1% | $-0.83-108.3% | $10.04+1281.2% | $-0.85+34.1% | $-1.29-7.5% | $-1.20+42.0% | $-2.07-17.6% | $-1.76 |
PTCT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6B+0.4% | $2.6B-0.8% | $2.7B+55.7% | $1.7B-11.0% | $1.9B+7.1% | $1.8B-5.6% | $1.9B+50.5% | $1.3B |
| Current Assets | $2.0B-11.7% | $2.3B-1.9% | $2.3B+69.6% | $1.4B+0.6% | $1.4B+16.2% | $1.2B-4.1% | $1.2B+125.5% | $540.4M |
| Cash & Equivalents | $672.6M-33.9% | $1.0B-31.3% | $1.5B+89.8% | $779.7M+19.1% | $654.8M+19.4% | $548.4M-7.7% | $594.0M+259.7% | $165.2M |
| Inventory | $52.7M+54.7% | $34.1M+57.1% | $21.7M-6.5% | $23.2M-27.1% | $31.8M+5.9% | $30.1M-1.7% | $30.6M-14.5% | $35.8M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M |
| Total Liabilities | $2.8B-1.5% | $2.8B0.0% | $2.8B+1.4% | $2.8B-3.2% | $2.9B+7.9% | $2.7B-1.1% | $2.7B+40.6% | $1.9B |
| Current Liabilities | $866.2M+38.0% | $627.8M+5.4% | $595.4M+2.5% | $581.0M-4.7% | $609.8M+6.1% | $574.5M-4.7% | $603.1M+22.6% | $492.1M |
| Long-Term Debt | N/A | $286.0M+0.1% | $285.7M+0.1% | $285.4M+0.2% | $284.8M+0.1% | $284.5M+0.1% | $284.2M-50.4% | $573.2M |
| Total Equity | -$155.8M+24.6% | -$206.5M-11.2% | -$185.8M+83.1% | -$1.1B-12.0% | -$980.2M-9.7% | -$893.9M-9.2% | -$818.6M-22.0% | -$670.8M |
| Retained Earnings | -$2.8B+0.6% | -$2.8B-2.3% | -$2.8B+23.8% | -$3.6B-5.0% | -$3.5B-2.9% | -$3.4B-2.8% | -$3.3B-5.0% | -$3.1B |
PTCT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$66.3M-13.7% | -$58.3M-106.7% | $870.1M+3000.0% | -$30.0M+58.0% | -$71.5M-201.0% | $70.8M+170.6% | -$100.3M-590.7% | -$14.5M |
| Capital Expenditures | $3.4M+161.6% | $1.3M-23.6% | $1.7M-54.2% | $3.8M+151.1% | -$7.4M-176.9% | $9.6M+72.3% | $5.6M-12.4% | $6.4M |
| Free Cash Flow | -$69.7M-16.9% | -$59.6M-106.9% | $868.4M+2671.4% | -$33.8M+57.2% | -$78.8M-228.9% | $61.2M+157.8% | -$105.9M-407.1% | -$20.9M |
| Investing Cash Flow | -$289.6M+31.4% | -$422.0M-128.9% | -$184.4M-168.9% | $267.7M+506.1% | -$65.9M+42.6% | -$114.9M-21.7% | -$94.4M-219.0% | -$29.6M |
| Financing Cash Flow | $15.2M+284.2% | $4.0M-57.9% | $9.4M-64.5% | $26.5M-89.3% | $246.5M+45544.8% | $540K-99.9% | $620.5M+18361.3% | $3.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PTCT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 1.4%+21.0pp | -19.5%-102.0pp | 82.5%+158.7pp | -76.2%-54.6pp | -21.5%+0.1pp | -21.6%-23.5pp | 1.9%+62.0pp | -60.1% |
| Net Margin | 7.5%+43.8pp | -36.3%-109.9pp | 73.7%+104.6pp | -30.9%+22.2pp | -53.1%-9.5pp | -43.6%+7.2pp | -50.7%+16.9pp | -67.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.6%+3.1pp | -2.5%-35.1pp | 32.6%+36.5pp | -3.9%+1.3pp | -5.2%-0.1pp | -5.1%+3.1pp | -8.2%+2.3pp | -10.5% |
| Current Ratio | 2.32-1.3 | 3.62-0.3 | 3.89+1.5 | 2.35+0.1 | 2.23+0.2 | 2.03+0.0 | 2.02+0.9 | 1.10 |
| Debt-to-Equity | -17.97-16.6 | -1.38+0.2 | -1.54-1.3 | -0.26+0.0 | -0.29+0.0 | -0.32+0.0 | -0.35+0.5 | -0.85 |
| FCF Margin | -33.1%+0.3pp | -33.4%-107.2pp | 73.8%+89.7pp | -15.8%+26.4pp | -42.2%-71.3pp | 29.1%+63.6pp | -34.5%-23.8pp | -10.6% |
Note: Shareholder equity is negative (-$1.1B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Ptc Therapeutics's annual revenue?
Ptc Therapeutics (PTCT) reported $806.8M in total revenue for fiscal year 2024. This represents a -14.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ptc Therapeutics's revenue growing?
Ptc Therapeutics (PTCT) revenue declined by 14% year-over-year, from $937.8M to $806.8M in fiscal year 2024.
Is Ptc Therapeutics profitable?
No, Ptc Therapeutics (PTCT) reported a net income of -$363.3M in fiscal year 2024, with a net profit margin of -45.0%.
What is Ptc Therapeutics's earnings per share (EPS)?
Ptc Therapeutics (PTCT) reported diluted earnings per share of $-4.73 for fiscal year 2024. This represents a 43.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Ptc Therapeutics's EBITDA?
Ptc Therapeutics (PTCT) had EBITDA of -$226.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Ptc Therapeutics have?
As of fiscal year 2024, Ptc Therapeutics (PTCT) had $779.7M in cash and equivalents against $285.4M in long-term debt.
What is Ptc Therapeutics's operating margin?
Ptc Therapeutics (PTCT) had an operating margin of -37.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Ptc Therapeutics's net profit margin?
Ptc Therapeutics (PTCT) had a net profit margin of -45.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Ptc Therapeutics's free cash flow?
Ptc Therapeutics (PTCT) generated -$114.2M in free cash flow during fiscal year 2024. This represents a 38.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ptc Therapeutics's operating cash flow?
Ptc Therapeutics (PTCT) generated -$107.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Ptc Therapeutics's total assets?
Ptc Therapeutics (PTCT) had $1.7B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ptc Therapeutics's capital expenditures?
Ptc Therapeutics (PTCT) invested $6.5M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ptc Therapeutics spend on research and development?
Ptc Therapeutics (PTCT) invested $534.5M in research and development during fiscal year 2024.
How many shares does Ptc Therapeutics have outstanding?
Ptc Therapeutics (PTCT) had 78M shares outstanding as of fiscal year 2024.
What is Ptc Therapeutics's current ratio?
Ptc Therapeutics (PTCT) had a current ratio of 2.35 as of fiscal year 2024, which is generally considered healthy.
What is Ptc Therapeutics's debt-to-equity ratio?
Ptc Therapeutics (PTCT) had a debt-to-equity ratio of -0.26 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ptc Therapeutics's return on assets (ROA)?
Ptc Therapeutics (PTCT) had a return on assets of -21.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ptc Therapeutics's cash runway?
Based on fiscal year 2024 data, Ptc Therapeutics (PTCT) had $779.7M in cash against an annual operating cash burn of $107.7M. This gives an estimated cash runway of approximately 87 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Ptc Therapeutics's debt-to-equity ratio negative or unusual?
Ptc Therapeutics (PTCT) has negative shareholder equity of -$1.1B as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Ptc Therapeutics's Piotroski F-Score?
Ptc Therapeutics (PTCT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ptc Therapeutics's earnings high quality?
Ptc Therapeutics (PTCT) has an earnings quality ratio of 0.30x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ptc Therapeutics?
Ptc Therapeutics (PTCT) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.